GENE ONLINE|News &
Opinion
Blog

2021-06-10| In-DepthR&DTechnology

New IO Targets and Resistance Mechanisms of Immune Checkpoint-Based Therapies

by Isha Kapoor
Share To
At the ASCO 2021 virtual annual meeting, Dr. Antoni Ribas from UCLA, Dr. Patrick Alexander Ott from Dana Farber together with Dr. Kurt A. Schalper from Yale University teamed to discuss resistance mechanisms of checkpoint inhibitors, potential therapeutic combinations, neoantigen landscape, tumor mutational burden, and the role of tumor microenvironment in cancer immunotherapy.

Therapeutic resistance can be of two types, viz, primary resistance- wherein patients generally do not respond to therapy, and acquired resistance- where patients respond initially but still undergo disease progression.

GO Prime with only $1.49 now

LATEST
Breakthrough Stem Cell Treatment Shows Promise in Reversing Liver Disease
2023-12-08
2023 Taiwan Healthcare Expo: Showcasing Innovative Advances in Biomedical Technology
2023-12-07
Absci Accelerates Breakthroughs in AI-Designed Drugs with AstraZeneca and Almirall Collaborations
2023-12-06
Saving Lives Through Communication, Heroic Faith Medical Science Showcasing Novel AI Auscultation Tool for Procedural Sedation Patients in PGA 77
2023-12-05
AbbVie Invests $10.1 Billion in ImmunoGen, Targeting the Ovarian Cancer Landscape
2023-12-05
PRISM BioLab and Eli Lilly Join Forces in Revolutionary Drug Discovery Collaboration
2023-12-05
Novel Hydrogel Delivery System Could Reduce Daily Diabetes Injections to Three Times a Year
2023-12-04
EVENT
Scroll to Top